1-(2-hydroxyethyl)-2-methylpiperazine | 3477-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2-hydroxyethyl)-2-methylpiperazine
• 英文别名: N-(2-Hydroxyethyl)-2-methylpiperazin；1-(2-Hydroxyethyl)-2-methyl-piperazin；2-(2-methyl-piperazin-1-yl)-ethanol；2-(2-Methylpiperazin-1-yl)ethan-1-ol；2-(2-methylpiperazin-1-yl)ethanol
• CAS: 3477-42-7
• 化学式: C₇H₁₆N₂O
• mdl: MFCD16842434
• 分子量: 144.217
• InChiKey: SDMNEUXIWBRMPK-UHFFFAOYSA-N

物化性质

• 沸点：
  134-136 °C(Press: 20 Torr)
• 密度：
  1.0050 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  、 1-(2-hydroxyethyl)-2-methylpiperazine 生成
  参考文献：
  名称：

  Small conformationally restricted piperidine N-arylsulfonamides as orally active γ-secretase inhibitors

  摘要：

  The design and development of a new class of small 2,6-disubstituted piperidine N-arylsulfonamide gamma-secretase inhibitors is reported. Lowering molecular weight including the use of conformational constraint led to compounds with less CYP 3A4 liability compared to early leads. Compounds active orally in lowering A beta levels in T-g CRND8 mice were identified as potential treatments for Alzheimer's disease. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.013
• 作为产物：
  描述：

  环氧乙烷 、 2-甲基哌嗪 以 various solvent(s) 为溶剂， 反应 0.5h， 以95%的产率得到1-(2-hydroxyethyl)-2-methylpiperazine
  参考文献：
  名称：

  Petrova, L. S.; Davidenkov, L. R.; Medved', S. S., Journal of applied chemistry of the USSR, 1980, vol. 53, # 1, p. 174 - 178

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS 515
  申请人：Ducray Richard

  公开号：US20100105655A1

  公开（公告）日：2010-04-29

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了化学式（I）的新型嘧啶衍生物或其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• Pyridine [3,4-b] Pyrazinones
  申请人：Hughes O. Robert

  公开号：US20070249615A1

  公开（公告）日：2007-10-25

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R 2 , R 6A , R 6B and R 8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.

  本文披露了化合物及其药用可接受的盐，其中化合物具有以下结构的Formula I：其中R2、R6A、R6B和R8如规范中定义。同时还披露了相应的药物组合物、治疗方法、合成方法和中间体。
• Crosslinkers for improving stability of polyurethane foams
  申请人：Vedage Gamini Ananda

  公开号：US20080090922A1

  公开（公告）日：2008-04-17

  A composition for making a polyurethane foam includes a non-fugitive tertiary amine urethane catalyst and an alkylated polyamine crosslinking additives. Foams prepared from the reaction of a polyol and an organic isocyanate in the presence of these ingredients show improved resistance to deterioration of physical properties upon humid aging.

  一种制备聚氨酯泡沫的配方包括非挥发性三级胺脲催化剂和烷基化聚胺交联添加剂。在这些成分的存在下，聚醚和有机异氰酸酯反应制备的泡沫在湿度老化时显示出改善的物理性能耐久性。
• POLYTHIOUREA COMPOSITIONS AND METHODS OF USE
  申请人：EMPIRE TECHNOLOGY DEVELOPMENT LLC

  公开号：US20150344613A1

  公开（公告）日：2015-12-03

  Disclosed herein are compositions and methods of making polythiourea and polythiourethane foams and coatings. In one embodiment, a method of preparing a polythiourea composition involves combining at least one polyamine compound, at least one polyisothiocyanate compound, and at least one catalyst to form a reaction mixture, and mixing the reaction mixture to form the polythiourea composition. In some embodiments, the polyamine compound may have an amine functionality of two or more, and is present in an amount of about 14 wt % to about 40 wt % of the reaction mixture. In some embodiments, the polyisothiocyanate compound may have a functionality of two or more, and is present in an amount of about 60 wt % to about 86 wt % of the reaction mixture. In some embodiments, the catalyst may be present in an amount of about 0 wt % to about 5 wt % of the reaction mixture.

  本文公开了制备聚硫脲和聚硫脲酯泡沫和涂层的组合物和方法。在一种实施例中，制备聚硫脲组合物的方法包括将至少一种多胺化合物、至少一种多异硫氰酸酯化合物和至少一种催化剂组合形成反应混合物，并混合反应混合物以形成聚硫脲组合物。在一些实施例中，多胺化合物可能具有两种或更多的胺官能团，并且在反应混合物中的含量约为14重量％至约40重量％。在一些实施例中，多异硫氰酸酯化合物可能具有两种或更多的官能团，并且在反应混合物中的含量约为60重量％至约86重量％。在一些实施例中，催化剂可能在反应混合物中的含量约为0重量％至约5重量％。
• Conversion of oxygen-containing polyamines
  申请人：UNION CARBIDE CORPORATION

  公开号：EP0197611A2

  公开（公告）日：1986-10-15

  Process for preparing polyalkylene polyamines by contacting an alkanolamine, such as, ethanolamine, and a reactive nitrogen-containing base which is ammonia or a primary or secondary amine, in a first reactor to produce an alkyleneamine, such as, ethylenediamine, and an aminoalkylalkanolåmine, such as, aminoethylethanolamine, in the presence of a catalytically effective amount of an amination catalyst and at a temperature and pressure sufficient to form the alkyleneamine and aminoalkylalkanolamine. Then the alkyleneamine, aminoalkylalkanolamine, unreacted alkanolamine and unreacted nitrogen-containing base are reacted in a second reactor to produce the polyalkylene polyamines, such as, diethylenetriamine, in the presence of a catalytically effective amount of an amination catalyst, such as, a reductive amination catalyst or a phosphorus-containing catalyst, and at a temperature and pressure sufficient to form the polyalkylene polyamines. Preferably the phosphorus-containing catalyst is a Group IIIB metal acid phosphate. By controlling the relative amounts of the feed components, one can achieve a desired molecular weight distribution and range in the polyalkylene polyamine product.

  制备聚亚烷基多胺的工艺：在第一反应器中，在催化有效量的胺化催化剂存在下，在足以形成亚烷基胺和氨基烷基醇胺的温度和压力下，使烷醇胺（如乙醇胺）和活性含氮碱（氨或伯胺或仲胺）接触，生成亚烷基胺（如乙二胺）和氨基烷基醇胺（如氨基乙基醇胺）。然后在第二反应器中，在催化有效量的胺化催化剂（如还原胺化催化剂或含磷催化剂）存在下，在足以形成聚亚烷基多胺的温度和压力下，使亚烷基胺、氨基烷醇胺、未反应的烷醇胺和未反应的含氮碱反应，生成聚亚烷基多胺（如二乙烯三胺）。含磷催化剂最好是 IIIB 族金属酸磷酸盐。通过控制进料组分的相对量，可以在聚亚烷基多胺产品中获得所需的分子量分布和范围。